News search
Research 13 Sep 2024 RESILIENCE is a clinical trial funded by the European Commission (H2020 Programme) that aims to reduce the prevalence of heart failure in cancer survivors |
Research 16 Apr 2024 The study, published in the journal JACC: CardioOncology, identifies mitochondrial function and heart metabolism as targets for possible treatments to protect against anthracycline-induced cardiotoxicity |
About the CNIC 19 Dec 2023 Dr. Carla Rothlin is Dorys McConnell Duberg Professor of Immunobiology and Professor of Pharmacology at the Yale School of Medicine, and co-leader of the Cancer Immunology Programme at Yale Cancer Centre. She studied biochemistry and pharmacology at the University of Buenos Aires, where she also undertook her postgraduate research under the direction of Dr. Ana Belén Elgoyhen, focussing on nicotinic receptors expressed in the inner ear. Later, she completed her doctorate and moved to San Diego to join Dr. Greg Lemke’s laboratory at the Salk Institute for Biological Studies. In 2009, Dr. Rothlin was named Assistant Professor in Immunobiology at Yale Medical School |
Research 29 May 2023 The new study, published in Nature Cardiovascular Research, will help to select the most effective and safe way to modulate angiogenesis in ischemic tissues or in cancer |
Research 9 Jun 2022 A study published in Hepatology demonstrates that the activation of thermogenesis in the livers of obese mice contributes to weight loss and improves diabetes symptoms |
About the CNIC 29 Jun 2021 Over one million European cancer patients suffer from side effects to chemotherapy |
About the CNIC 17 Jun 2021 The jury acknowledged this CNIC researcher's contribution to understanding why obesity causes cardiometabolic diseases. |
About the CNIC 10 Jun 2021 The €35,000 awarded by the foundation in each category is for research that deepens knowledge of the relationship between nutrition, food and health |
About the CNIC 9 Jun 2021 The study, published in Nature in 2019, revealed relevant data about the involvement of the protein p38gamma in the development of the main type of primary liver cancer, which affects over a million people a year worldwide |
Research 14 May 2021 Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have designed a new strategy to potentiate immunotherapy, the treatment that has revolutionized cancer management |
- 1 of 3
- next ›